<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35085">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827020</url>
  </required_header>
  <id_info>
    <org_study_id>Mukadder</org_study_id>
    <nct_id>NCT01827020</nct_id>
  </id_info>
  <brief_title>Effect of Ketamine Addition to Lidocaine in Rhinoplasty</brief_title>
  <official_title>Effect of Ketamine Addition to Lidocaine for Postoperative Pain Management in Rhinoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether subanesthetic ketamine addition to
      lidocaine decreases postoperative pain scores in infiltration anesthesia during rhinoplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In rhinoplasty operations local infiltration anesthesia uses for surgery insight and patient
      comfort. The investigators designed this study to prolonged the time of infiltration block
      and preventive analgesia. So, before operation, study drugs will infiltrate to the submucosa
      of intranasal cavity. Then, surgeon and patient satisfaction, postoperative analgesic
      demand, postoperative pain scores and side effects will determine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postoperative pain scores on the Visual Analogue Scale</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pain scores will examine with Visual analogue scale (VAS, 0-100) in the first 24 hours of postoperative period. The examination will repeated in different time period(5.min, 15.min, 30.min, 1 h, 2h,4.h, 6.h, 8.h, 16.h, 24.h). Patients that have VAS&gt;40 will receive 1mg/kg tramadol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>24 hour</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At the end of postoperative 24 h, the patient satisfaction will examine by a score as (1 poor, 2 middle, 3 good, 4 perfect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic demand</measure>
    <time_frame>24 hour</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At the first day of postoperative period, analgesic requirement will record. When Visual analogue scale &gt; 40, intravenous 1 mg/kg tramadol bolus will give.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse effects as a measure of safety and tolerability</measure>
    <time_frame>24 hour</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sedation, nausea and vomiting, dizziness, and hallucination will examine as an adverse effect in all patients.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Nose Deformities, Acquired</condition>
  <arm_group>
    <arm_group_label>Group L (number of participants=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K (number of participants=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg  plus lidocaine 2% 1 mg/kg  of the intranasal cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S  (number of participants=30)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2 %</intervention_name>
    <description>12 mL lidocaine 2% 1mg/kg</description>
    <arm_group_label>Group L (number of participants=30)</arm_group_label>
    <other_name>preincisional infiltration of lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine plus Lidocaine</intervention_name>
    <description>ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL</description>
    <arm_group_label>Group K (number of participants=30)</arm_group_label>
    <other_name>preincisional infiltration of ketamine plus lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>12 mL saline (0.9% isotonic solution)</description>
    <arm_group_label>Group S  (number of participants=30)</arm_group_label>
    <other_name>preincisional infiltration of saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective rhinoplasty operation under general anesthesia

          -  Patients with ASA (American Society of Anesthesiology) class I

          -  Patients between 18-50 years old

        Exclusion Criteria:

          -  Age &lt;18 and &gt;50

          -  ASA &gt; II

          -  Preexisting neurological or psychiatric illness

          -  Systemic diseases (diabetes mellitus, hypertension, coronary heart disease...)

          -  Having a history of chronic pain and receiving chronic analgesia therapy

          -  Having a history of drug abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mukadder Sanli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turgut Ozal Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turgut Ozal Medical Center</name>
      <address>
        <city>Malatya</city>
        <zip>44315</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Honarmand A, Safavi M, Karaky H. Preincisional administration of intravenous or subcutaneous infiltration of low-dose ketamine suppresses postoperative pain after appendectomy. J Pain Res. 2012;5:1-6. doi: 10.2147/JPR.S26476. Epub 2011 Dec 30.</citation>
    <PMID>22328829</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 8, 2013</lastchanged_date>
  <firstreceived_date>March 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Mukadder Sanli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Nose Deformities, Acquired</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
